KR880001285A - 약용 서방 기제 - Google Patents

약용 서방 기제 Download PDF

Info

Publication number
KR880001285A
KR880001285A KR1019870007755A KR870007755A KR880001285A KR 880001285 A KR880001285 A KR 880001285A KR 1019870007755 A KR1019870007755 A KR 1019870007755A KR 870007755 A KR870007755 A KR 870007755A KR 880001285 A KR880001285 A KR 880001285A
Authority
KR
South Korea
Prior art keywords
pharmaceutical composition
composition according
matrix
acrylic resin
center
Prior art date
Application number
KR1019870007755A
Other languages
English (en)
Other versions
KR930008954B1 (ko
Inventor
오스락크 벤자민
Original Assignee
마르틴 그린
유로셀띠끄 소시에떼 아노님
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=25390936&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR880001285(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 마르틴 그린, 유로셀띠끄 소시에떼 아노님 filed Critical 마르틴 그린
Publication of KR880001285A publication Critical patent/KR880001285A/ko
Application granted granted Critical
Publication of KR930008954B1 publication Critical patent/KR930008954B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

내용 없음

Description

약용 서방 기제
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (16)

10 내지 18개의 탄소원자의 고급 지방족 알코올 및 상기 고급 지방족 알코올에 아크릴수지를 합한 중량의 약 10 내지 60중량%의 양의 약학적으로 허용 가능한 아크릴수지로 되어 있는 제어방출 중심 또는 매트릭스에 분산된 제약 활성제로 구성되는 것을 특징으로 하는 구강투여용 확장작용 제어 방출 제약 조성물.
제1항에 있어서, 상기 아크릴 수지가 약 15 내지 40중량%의 양인 것을 특징으로 하는 제약조성물.
제1항에 있어서, 상기 아크릴수지가 약 20 내지 35중량%의 양인 것을 특징으로 하는 제약조성물.
제1항에 있어서, 상기 중심 또는 매트릭스 또한 접합제를 함유하는 것을 특징으로 하는 제약조성물.
제4항에 있어서, 상기 중심 또는 매트릭스 또한 충전제를 함유하는 것을 특징으로 하는 제약조성물.
제5항에 있어서, 상기 중심 또는 매트릭스 또한 붕해재를 함유하는 것을 특징으로 하는 제약조성물.
제6항에 있어서, 상기 중심 또는 매트릭스 또한 윤활유를 함유하는 것을 특징으로 하는 제약조성물.
제1항에 있어서, 상기 중심 또는 매트릭스가 상기 조성물의 약 20 내지 40중량%로 구성되는 것을 특징으로 하는 제약조성물.
제1항에 있어서, 상기 제약 활성제가 수용성이 높은 것을 특징으로 하는 제약조성물.
제1항에 있어서, 상기 약제가 아미트리프탈린, 아트로핀, 클로트페니라민, 클로르프로미진, 코데인, 댁스브롬페니라민, 디페닐히드라민, 독실아민, 에페드린, 히오스시아민, 모르핀, 옥시코돈, 파파바린, 페닐프로판올아민, 프로프라놀올, 퀴니딘, 스코프라민, 테오필린 또는 티오리다진인것을 특징으로 하는 약제조성물.
10 내지 18개의 탄소원자의 공급지방족 알코올 및 상기 고급 지방족 알코올과 아크릴수지 중량이 약 10 내지 60중량%의 양으로 존재하는 약학적으로 허용 가능한 아클릴수지로 구성되는 것을 특징으로 하는 구강 투여용 제어방출 약학조성물 및 그의 제약 활성제 분배에 알맞는 중심 또는 매트릭스.
제11항에 있어서, 상기 아크릴수지의 양이 약 15 내지 40중량%인 것을 특징으로 하는 중심 또는 매트릭스.
제11항에 있어서, 상기 아크릴수지의 양이 약 20 내지 35중량%인 것을 특징으로 하는 중심 또는 매트릭스.
제1항에 있어서, 정제형으로 존재하는 것을 특징으로 하는 제약조성물.
제1항에 있어서, 개프렛형으로 존재하는 것을 특징으로 하는 제약조성물.
제1항에 있어서, 캡슐형으로 존재하는 것을 특징으로 하는 제약조성물.
※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019870007755A 1986-07-18 1987-07-16 약용 서방 기제 KR930008954B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US887340 1986-07-18
US06/887,340 US4861598A (en) 1986-07-18 1986-07-18 Controlled release bases for pharmaceuticals
US887,340 1986-07-18

Publications (2)

Publication Number Publication Date
KR880001285A true KR880001285A (ko) 1988-04-22
KR930008954B1 KR930008954B1 (ko) 1993-09-17

Family

ID=25390936

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870007755A KR930008954B1 (ko) 1986-07-18 1987-07-16 약용 서방 기제

Country Status (22)

Country Link
US (1) US4861598A (ko)
EP (1) EP0253104B1 (ko)
JP (2) JP2511054B2 (ko)
KR (1) KR930008954B1 (ko)
CN (1) CN1029770C (ko)
AT (1) ATE62404T1 (ko)
AU (1) AU596183B2 (ko)
CA (1) CA1296633C (ko)
DE (1) DE3769221D1 (ko)
DK (1) DK175627B1 (ko)
DZ (1) DZ1112A1 (ko)
EG (1) EG18574A (ko)
ES (1) ES2033259T3 (ko)
FI (1) FI87045C (ko)
GR (1) GR3001788T3 (ko)
IL (1) IL82604A (ko)
IN (1) IN166546B (ko)
MX (1) MX163284A (ko)
NO (1) NO169998C (ko)
NZ (1) NZ220406A (ko)
PT (1) PT85353B (ko)
ZA (1) ZA874038B (ko)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230000634U (ko) 2021-09-16 2023-03-23 장상환 분리가능한 쇠스랑

Families Citing this family (140)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4970075A (en) * 1986-07-18 1990-11-13 Euroceltique, S.A. Controlled release bases for pharmaceuticals
US5266331A (en) * 1991-11-27 1993-11-30 Euroceltique, S.A. Controlled release oxycodone compositions
US5478577A (en) * 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
US5681585A (en) * 1991-12-24 1997-10-28 Euro-Celtique, S.A. Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer
US5958459A (en) * 1991-12-24 1999-09-28 Purdue Pharma L.P. Opioid formulations having extended controlled released
US20080075781A1 (en) * 1992-11-25 2008-03-27 Purdue Pharma Lp Controlled release oxycodone compositions
NZ260408A (en) 1993-05-10 1996-05-28 Euro Celtique Sa Controlled release preparation comprising tramadol
US20070275062A1 (en) * 1993-06-18 2007-11-29 Benjamin Oshlack Controlled release oxycodone compositions
IL110014A (en) * 1993-07-01 1999-11-30 Euro Celtique Sa Solid controlled-release oral dosage forms of opioid analgesics
US7740881B1 (en) 1993-07-01 2010-06-22 Purdue Pharma Lp Method of treating humans with opioid formulations having extended controlled release
IL109944A (en) * 1993-07-01 1998-12-06 Euro Celtique Sa Continuous release dosage form containing morphine and a method of preparing such sustained release unit dosage forms
US5879705A (en) * 1993-07-27 1999-03-09 Euro-Celtique S.A. Sustained release compositions of morphine and a method of preparing pharmaceutical compositions
EP1442745A1 (en) * 1993-10-07 2004-08-04 Euro-Celtique Orally administrable opioid formulations having extended duration of effect
KR100354702B1 (ko) * 1993-11-23 2002-12-28 유로-셀티크 소시에떼 아노뉨 약학조성물의제조방법및서방형조성물
US5891471A (en) * 1993-11-23 1999-04-06 Euro-Celtique, S.A. Pharmaceutical multiparticulates
US5843480A (en) * 1994-03-14 1998-12-01 Euro-Celtique, S.A. Controlled release diamorphine formulation
US5430021A (en) * 1994-03-18 1995-07-04 Pharmavene, Inc. Hydrophobic drug delivery systems
US5484608A (en) * 1994-03-28 1996-01-16 Pharmavene, Inc. Sustained-release drug delivery system
ES2097087B1 (es) * 1994-08-01 1997-12-16 Univ Sevilla Sistema de liberacion controlada de morfina y otros farmacos solubles en agua por complejacion con sustancias polimericas.
GB9422154D0 (en) * 1994-11-03 1994-12-21 Euro Celtique Sa Pharmaceutical compositions and method of producing the same
US5965161A (en) * 1994-11-04 1999-10-12 Euro-Celtique, S.A. Extruded multi-particulates
US20020006438A1 (en) * 1998-09-25 2002-01-17 Benjamin Oshlack Sustained release hydromorphone formulations exhibiting bimodal characteristics
GB9519363D0 (en) 1995-09-22 1995-11-22 Euro Celtique Sa Pharmaceutical formulation
US5811126A (en) * 1995-10-02 1998-09-22 Euro-Celtique, S.A. Controlled release matrix for pharmaceuticals
JPH1050306A (ja) * 1996-07-31 1998-02-20 Toyota Autom Loom Works Ltd 水素吸蔵合金電極の製造方法
PT1041987E (pt) 1997-12-22 2006-07-31 Euro Celtique Sa Forma farmaceutica de dosagem oral, compreendendo uma combinacao de um agonista de opioide e naltrexona
US6375957B1 (en) 1997-12-22 2002-04-23 Euro-Celtique, S.A. Opioid agonist/opioid antagonist/acetaminophen combinations
WO2000016776A1 (fr) * 1998-09-18 2000-03-30 Takeda Chemical Industries, Ltd. Preparations a administrer par voie buccale a liberation lente
US6806294B2 (en) 1998-10-15 2004-10-19 Euro-Celtique S.A. Opioid analgesic
DE19918325A1 (de) 1999-04-22 2000-10-26 Euro Celtique Sa Verfahren zur Herstellung von Arzneiformen mit regulierter Wirkstofffreisetzung mittels Extrusion
ATE526950T1 (de) 1999-10-29 2011-10-15 Euro Celtique Sa Hydrocodon-formulierungen mit gesteuerter freisetzung
US10179130B2 (en) 1999-10-29 2019-01-15 Purdue Pharma L.P. Controlled release hydrocodone formulations
EP2092936B1 (en) 2000-02-08 2013-03-20 Euro-Celtique S.A. Tamper-resistant oral opioid agonist formulations
US6716449B2 (en) 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
IL151058A0 (en) 2000-02-08 2003-04-10 Euro Celtique Sa Controlled-release compositions containing opioid agonist and antagonist
WO2002036099A1 (en) 2000-10-30 2002-05-10 Euro-Celtique S.A. Controlled release hydrocodone formulations
UA81224C2 (uk) * 2001-05-02 2007-12-25 Euro Celtic S A Дозована форма оксикодону та її застосування
US20110104214A1 (en) * 2004-04-15 2011-05-05 Purdue Pharma L.P. Once-a-day oxycodone formulations
EP1387673B1 (en) 2001-05-11 2010-12-29 Endo Pharmaceuticals Inc. Abuse-resistant controlled-release opioid dosage form
US8329216B2 (en) * 2001-07-06 2012-12-11 Endo Pharmaceuticals Inc. Oxymorphone controlled release formulations
DK1404331T3 (da) * 2001-07-06 2008-01-28 Penwest Pharmaceuticals Co Sustained release-formuleringer af oxymorphon
CN1268338C (zh) * 2001-07-06 2006-08-09 恩德制药公司 用作止痛剂的6－羟基羟吗啡酮的口服给药
ATE419039T1 (de) 2001-07-18 2009-01-15 Euro Celtique Sa Pharmazeutische kombinationen von oxycodon und naloxon
US20030068375A1 (en) 2001-08-06 2003-04-10 Curtis Wright Pharmaceutical formulation containing gelling agent
WO2003013433A2 (en) 2001-08-06 2003-02-20 Euro-Celtique S.A. Sequestered antagonist formulations
US20030044458A1 (en) 2001-08-06 2003-03-06 Curtis Wright Oral dosage form comprising a therapeutic agent and an adverse-effect agent
RU2004106619A (ru) 2001-08-06 2005-07-10 Эро-Селтик С.А. (Lu) Композиции опиоидного агониста, содержащие высвобождаемый и изолированный антагонист
US20030091635A1 (en) * 2001-09-26 2003-05-15 Baichwal Anand R. Opioid formulations having reduced potential for abuse
ES2733051T1 (es) 2002-04-05 2019-11-27 Euro Celtique Sa Matriz para liberación sostenida, invariable e independiente de compuestos activos
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
US20050106249A1 (en) * 2002-04-29 2005-05-19 Stephen Hwang Once-a-day, oral, controlled-release, oxycodone dosage forms
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
MXPA04012021A (es) * 2002-05-31 2005-08-16 Johnson & Johnson Formas de dosis y composiciones para la administracion osmotica de dosis variables de oxicodona.
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
AU2003247876B2 (en) 2002-07-05 2006-10-05 Collegium Pharmaceutical, Inc Abuse-deterrent pharmaceutical compositions of opiods and other drugs
US8557291B2 (en) * 2002-07-05 2013-10-15 Collegium Pharmaceutical, Inc. Abuse-deterrent pharmaceutical compositions of opioids and other drugs
US8840928B2 (en) 2002-07-05 2014-09-23 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US10004729B2 (en) 2002-07-05 2018-06-26 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
US20050020613A1 (en) * 2002-09-20 2005-01-27 Alpharma, Inc. Sustained release opioid formulations and method of use
DK1551372T3 (en) 2002-09-20 2018-07-23 Alpharma Pharmaceuticals Llc SEQUERATION SUBSTANCES AND RELATED COMPOSITIONS AND PROCEDURES
US20040110781A1 (en) * 2002-12-05 2004-06-10 Harmon Troy M. Pharmaceutical compositions containing indistinguishable drug components
PT2218448E (pt) 2002-12-13 2016-01-26 Durect Corp Sistema oral de entrega de fármaco que compreende materiais transportadores líquidos de alta viscosidade
US20040202717A1 (en) 2003-04-08 2004-10-14 Mehta Atul M. Abuse-resistant oral dosage forms and method of use thereof
TWI347201B (en) 2003-04-21 2011-08-21 Euro Celtique Sa Pharmaceutical products,uses thereof and methods for preparing the same
EP1479381A1 (en) * 2003-05-19 2004-11-24 Euro-Celtique S.A. Pharmaceutical dosage form comprising a solid solution
US20060165790A1 (en) * 2003-06-27 2006-07-27 Malcolm Walden Multiparticulates
TWI357815B (en) * 2003-06-27 2012-02-11 Euro Celtique Sa Multiparticulates
SI1663229T1 (sl) 2003-09-25 2010-08-31 Euro Celtique Sa Farmacevtske kombinacije hidrokodona in naltreksona
WO2005034859A2 (en) * 2003-10-03 2005-04-21 Elite Laboratories Inc. Extended release formulations of opioids and method of use thereof
PT1691811E (pt) 2003-12-11 2014-10-30 Sunovion Pharmaceuticals Inc Combinação de um sedativo e de um modulador de neurotransmissores e métodos para melhorar a qualidade do sono e tratamento da depressão
EP1729730B1 (en) * 2004-03-30 2009-01-07 Euro-Celtique S.A. Tamper resistant dosage form comprising an adsorbent and an adverse agent
TWI483944B (zh) * 2004-03-30 2015-05-11 Euro Celtique Sa 含有小於２５ｐｐｍ１４-羥可待因酮之羥可酮鹽酸鹽組成物、醫藥劑型、延遲釋出口服劑型及醫藥上可以接受的包裝
US20050226929A1 (en) * 2004-04-12 2005-10-13 Jianbo Xie Controlled release opioid analgesic formulation
US20050266082A1 (en) * 2004-05-26 2005-12-01 Patel Satishkumar A Preparation of stable paroxetine HC1 ER tablets using a melt granulation process
EP1604666A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the Chronic Obstructive Pulmonary Disease (COPD)
EP1604667A1 (en) 2004-06-08 2005-12-14 Euro-Celtique S.A. Opioids for the treatment of the restless leg syndrome
LT1765292T (lt) 2004-06-12 2018-01-10 Collegium Pharmaceutical, Inc. Nuo piktnaudžiavimo apsaugotos vaistų formos
US9308164B2 (en) 2004-06-30 2016-04-12 Sovereign Pharmaceuticals, Llc Hyoscyamine dosage form
GB2418854B (en) 2004-08-31 2009-12-23 Euro Celtique Sa Multiparticulates
SI2415484T1 (sl) 2004-09-17 2014-10-30 Durect Corporation Pripravek, ki vsebuje lokalni anestetik SAIB, s podaljšanim sproščanjem
TWI369203B (en) 2004-11-22 2012-08-01 Euro Celtique Sa Methods for purifying trans-(-)-△9-tetrahydrocannabinol and trans-(+)-△9-tetrahydrocannabinol
GEP20105052B (en) * 2005-01-28 2010-07-26 Euro Celtique Sa Alcohol resistant dosage forms
EP1695700A1 (en) * 2005-02-28 2006-08-30 Euro-Celtique S.A. Dosage form containing oxycodone and naloxone
EP1702558A1 (en) 2005-02-28 2006-09-20 Euro-Celtique S.A. Method and device for the assessment of bowel function
EP1855647A4 (en) * 2005-03-04 2010-11-17 Intelgenx Corp DELAYED RELEASE PHARMACEUTICAL ORAL DOSAGE FORM AND METHOD OF MANUFACTURING THE SAME
MY148074A (en) * 2005-05-10 2013-02-28 Novartis Ag Pharmaceutical compositions comprising imatinib and a release retardant
PL2168585T3 (pl) 2005-06-09 2012-05-31 Euro Celtique Sa Kompozycje farmaceutyczne steroidów neuroaktywnych i ich zastosowania
TWI366460B (en) 2005-06-16 2012-06-21 Euro Celtique Sa Cannabinoid active pharmaceutical ingredient for improved dosage forms
WO2007002597A2 (en) 2005-06-27 2007-01-04 Biovail Laboratories International S.R.L. Modified-release formulations of a bupropion salt
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
EP1813276A1 (en) * 2006-01-27 2007-08-01 Euro-Celtique S.A. Tamper resistant dosage forms
US20070190141A1 (en) * 2006-02-16 2007-08-16 Aaron Dely Extended release opiate composition
US20070212414A1 (en) * 2006-03-08 2007-09-13 Penwest Pharmaceuticals Co. Ethanol-resistant sustained release formulations
US20070281017A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and metal hydroxide
US20070281016A1 (en) * 2006-06-06 2007-12-06 Endo Pharmaceuticals Inc., A Delaware Corporation Sustained release oxycodone composition with acrylic polymer and surfactant
US20080069891A1 (en) * 2006-09-15 2008-03-20 Cima Labs, Inc. Abuse resistant drug formulation
KR20150029762A (ko) 2006-06-19 2015-03-18 알파마 파머슈티컬스 엘엘씨 약제학적 조성물
CA2671197A1 (en) * 2006-07-21 2008-01-24 Lab International Srl Hydrophobic abuse deterrent delivery system
JP2010501011A (ja) * 2006-08-16 2010-01-14 オースペックス・ファーマシューティカルズ・インコーポレイテッド オピオイド鎮痛薬の調製および効用
SA07280459B1 (ar) 2006-08-25 2011-07-20 بيورديو فارما إل. بي. أشكال جرعة صيدلانية للتناول عن طريق الفم مقاومة للعبث تشتمل على مسكن شبه أفيوني
US8445018B2 (en) 2006-09-15 2013-05-21 Cima Labs Inc. Abuse resistant drug formulation
PT2117521E (pt) 2006-11-03 2012-09-10 Durect Corp Sistemas de administração transdérmica que compreendem bupivacaína
US20080220064A1 (en) * 2006-12-06 2008-09-11 Ramesh Ketkar Anant Extended release matrix formulations of morphine
GB0624880D0 (en) * 2006-12-14 2007-01-24 Johnson Matthey Plc Improved method for making analgesics
US8202542B1 (en) 2007-05-31 2012-06-19 Tris Pharma Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
US20090124650A1 (en) * 2007-06-21 2009-05-14 Endo Pharmaceuticals, Inc. Method of Treating Pain Utilizing Controlled Release Oxymorphone Pharmaceutical Compositions and Instructions on Effects of Alcohol
EP3326621A1 (en) * 2007-12-06 2018-05-30 Durect Corporation Oral pharmaceutical dosage forms
US8623418B2 (en) 2007-12-17 2014-01-07 Alpharma Pharmaceuticals Llc Pharmaceutical composition
US20090246276A1 (en) 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
US20100003322A1 (en) * 2008-07-03 2010-01-07 Lai Felix S Enteric coated hydrophobic matrix formulation
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
MY152279A (en) 2009-03-10 2014-09-15 Euro Celtique Sa Immediate release pharmaceutical compositions comprising oxycodone and naloxone
FR2946533A1 (fr) 2009-06-12 2010-12-17 Ethypharm Sa Reduction des fluctuations plasmatiques d'opioides.
US10668060B2 (en) 2009-12-10 2020-06-02 Collegium Pharmaceutical, Inc. Tamper-resistant pharmaceutical compositions of opioids and other drugs
MX2012012991A (es) 2010-05-11 2012-11-30 Cima Labs Inc Formas de dosificacion oral de liberacion prolongada resistentes al alcohol y que contienen metoprolol.
AU2011346757B2 (en) 2010-12-22 2015-08-20 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
JP5638151B2 (ja) 2010-12-23 2014-12-10 パーデュー、ファーマ、リミテッド、パートナーシップ 不正加工抵抗性の（ｔａｍｐｅｒｒｅｓｉｓｔａｎｔ）固形経口剤形
US20130143867A1 (en) 2011-12-02 2013-06-06 Sychroneuron Inc. Acamprosate formulations, methods of using the same, and combinations comprising the same
ES2716570T3 (es) 2012-04-17 2019-06-13 Purdue Pharma Lp Sistemas y procedimientos para tratar o prevenir una respuesta farmacodinámica adversa inducida por opioides
TW201639855A (zh) 2012-07-16 2016-11-16 羅德科技公司 改良之類鴉片合成方法
WO2014013313A1 (en) 2012-07-16 2014-01-23 Rhodes Technologies Process for improved opioid synthesis
WO2014123899A1 (en) 2013-02-05 2014-08-14 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9555113B2 (en) 2013-03-15 2017-01-31 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
CN105431144A (zh) 2013-06-05 2016-03-23 思康脑侒股份有限公司 阿坎酸制剂、使用阿坎酸制剂的方法以及包含阿坎酸制剂的组合
MY183489A (en) 2013-07-23 2021-02-22 Euro Celtique Sa A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation
US9120800B2 (en) 2013-08-02 2015-09-01 Johnson Matthey Public Limited Company Process for the preparation of oxymorphone alkaloid and oxymorphone salts
TWI539952B (zh) 2014-01-15 2016-07-01 羅德科技公司 改良氧化嗎啡酮合成之方法
JP2017502991A (ja) 2014-01-15 2017-01-26 ローズ テクノロジーズ 改良されたオキシコドン合成のための方法
US9062063B1 (en) 2014-03-21 2015-06-23 Johnson Matthey Public Limited Company Forms of oxymorphone hydrochloride
US9849124B2 (en) 2014-10-17 2017-12-26 Purdue Pharma L.P. Systems and methods for treating an opioid-induced adverse pharmacodynamic response
US9918979B2 (en) 2015-01-29 2018-03-20 Johnson Matthey Public Limited Company Process of preparing low ABUK oxymorphone hydrochloride
US9861629B1 (en) 2015-10-07 2018-01-09 Banner Life Sciences Llc Opioid abuse deterrent dosage forms
CA3003950C (en) 2015-10-23 2020-05-12 Kashiv Pharma Llc Enhanced abuse-deterrent formulations of oxycodone
US10335405B1 (en) 2016-05-04 2019-07-02 Patheon Softgels, Inc. Non-burst releasing pharmaceutical composition
US9737530B1 (en) 2016-06-23 2017-08-22 Collegium Pharmaceutical, Inc. Process of making stable abuse-deterrent oral formulations
US10335375B2 (en) 2017-05-30 2019-07-02 Patheon Softgels, Inc. Anti-overingestion abuse deterrent compositions
WO2019087084A1 (en) 2017-11-02 2019-05-09 Eman Biodiscoveries Sd. Bhd. Extract of orthosiphon stamineus, formulations, and uses thereof
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2805977A (en) * 1955-01-04 1957-09-10 Smith Kline French Lab Sustained release pharmaceutical preparation
GB1405088A (en) * 1971-06-03 1975-09-03 Mundipharma Ag Slow release formulation
US3965256A (en) * 1972-05-16 1976-06-22 Synergistics Slow release pharmaceutical compositions
SE418247B (sv) * 1975-11-17 1981-05-18 Haessle Ab Sett att framstella kroppar med reglerad frigoring av en aktiv komponent
SE7813246L (sv) * 1978-12-22 1980-06-23 Haessle Ab Fast farmaceutisk beredning innehallande kroppar med flera ytskikt
SE8003805L (sv) * 1980-05-21 1981-11-22 Haessle Ab En farmaceutisk beredning med forbettrade utlosningsegenskap
ATE14379T1 (de) * 1981-04-27 1985-08-15 Haessle Ab Pharmazeutisches praeparat.
DE3124983A1 (de) * 1981-06-25 1983-01-20 Meditest Inst Fuer Medizinisch Arzneiformen zur oralen verabreichung
US4443428A (en) * 1982-06-21 1984-04-17 Euroceltique, S.A. Extended action controlled release compositions
DK58983D0 (da) * 1983-02-11 1983-02-11 Leo Pharm Prod Ltd Farmaceutisk praeparat
JPS6143108A (ja) * 1984-08-03 1986-03-01 Nippon Shinyaku Co Ltd 医薬品製剤及びその製造法
NL8500724A (nl) * 1985-03-13 1986-10-01 Univ Groningen Inrichtingen voor geregelde afgifte van werkzame stoffen, alsmede werkwijze ter vervaardiging daarvan.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230000634U (ko) 2021-09-16 2023-03-23 장상환 분리가능한 쇠스랑

Also Published As

Publication number Publication date
NO872989L (no) 1988-01-19
JP2661646B2 (ja) 1997-10-08
NO169998B (no) 1992-05-25
EP0253104B1 (en) 1991-04-10
AU596183B2 (en) 1990-04-26
CA1296633C (en) 1992-03-03
JPH09136845A (ja) 1997-05-27
CN87104429A (zh) 1988-01-27
PT85353A (en) 1987-08-01
IN166546B (ko) 1990-06-02
EG18574A (en) 1993-08-30
AU7340387A (en) 1988-01-21
NO169998C (no) 1992-09-02
ES2033259T3 (es) 1993-03-16
MX163284A (es) 1992-04-03
NO872989D0 (no) 1987-07-17
DE3769221D1 (de) 1991-05-16
JPS6330427A (ja) 1988-02-09
US4861598A (en) 1989-08-29
DK367687D0 (da) 1987-07-15
FI872917A0 (fi) 1987-07-01
PT85353B (pt) 1990-04-30
IL82604A0 (en) 1987-11-30
IL82604A (en) 1990-08-31
ZA874038B (en) 1987-12-04
FI87045C (fi) 1992-11-25
KR930008954B1 (ko) 1993-09-17
EP0253104A1 (en) 1988-01-20
ATE62404T1 (de) 1991-04-15
JP2511054B2 (ja) 1996-06-26
DZ1112A1 (fr) 2004-09-13
DK175627B1 (da) 2004-12-27
NZ220406A (en) 1989-08-29
FI872917A (fi) 1988-01-19
GR3001788T3 (en) 1992-11-23
FI87045B (fi) 1992-08-14
CN1029770C (zh) 1995-09-20
DK367687A (da) 1988-01-19

Similar Documents

Publication Publication Date Title
KR880001285A (ko) 약용 서방 기제
KR930005616A (ko) 의약용 방출조절 매트릭스
ES2177609T3 (es) Pluma de administracion de medicacion con una escala para fijacion de la dosis.
KR880010758A (ko) 서방성 제제
KR880001288A (ko) 경구투여 형태의 서방성 약제학적 조성물
SE8303531D0 (sv) Farmaceutisk komposition
ES2070261T3 (es) Parche analgesico antiinflamatorio.
BR9912760A (pt) Usos de gama vinilgaba (gvg) e de uma composição que aumenta os nìveis de gaba do sistema nervoso central
IL80149A (en) Pharmaceutical compositions containing toluidide derivatives against graft-versus-host diseases and autoimmune diseases
KR900011452A (ko) 압출 가능한 탄성 구강 제약학적 겔 조성물
ES2001391A6 (es) Procedimiento de obtencion de una composicion farmaceutica para el tratamiento de senos faciales y nasales, alergias y sintomas de resfriado.
KR890004686A (ko) 서방성 에토돌락
KR880010759A (ko) 방출 조절성 제제
NZ332215A (en) Transdermally administered dextromethorphan as antitussive agent
KR830005854A (ko) 알카리성 진통제 캡슐의 제조방법
DK616186D0 (da) Farmaceutisk praeparat med retarderet frigivelse af ibuprofen
RS49602B (sr) Farmaceutske mikrosfere valproinske kiseline za oralnu upotrebu
ES2016620B3 (es) Sistema para liberar medicamentos con bioaceptabilidad mejorada.
DE69332378D1 (de) Perkutan verabreichbare basiszusammensetzung und daraus hergestellte zusammensetzung
GB2089210A (en) Polymeric diffusion matrix for administration of drugs
KR890006227A (ko) 페놀-함유 진해성 액체 조성물
FR2391202A1 (fr) Triazines-1,2,4 substituees, actives pharmacologiquement et medicaments contenant ces triazines
CO4750645A1 (es) Metodo de preparacion de granulos que incorporan un medica- mento para uso farmaceutico
ES2188670T3 (es) Formulaciones que contienen codeina.
GR900300082T1 (en) Use of dapiprazole for the manufacture of a pharmaceutical composition inhibiting the development of tolerance in the analgesic treatment with morphine

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20070821

Year of fee payment: 15

EXPY Expiration of term